Vitamin D metabolism and activity in the parathyroid gland

Molecular and Cellular Endocrinology

Volumn 347, Issue 1-2, 2011, Pages 30-41

  Bienaimé, Frank ^a,b   Prié, Dominique ^a,b   Friedlander, Gérard ^a,b   Souberbielle, Jean Claude ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

Author keywords

Parathyroid; PTH; Vitamin D

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM ION; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KLOTHO PROTEIN; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

CALCIUM HOMEOSTASIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC KIDNEY DISEASE; ENZYME REGULATION; HORMONE ACTION; HUMAN; HYDROXYLATION; HYPERPARATHYROIDISM; MARKER GENE; MOLECULAR INTERACTION; NONHUMAN; OSTEOPOROSIS; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PTH GENE; REVIEW; UPREGULATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

CALCIUM; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GLUCURONIDASE; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; PARATHYROID GLANDS; PARATHYROID HORMONE; RECEPTORS, CALCITRIOL; RECEPTORS, CALCIUM-SENSING; VITAMIN D;

EID: 82455208874     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.031     Document Type: Review

References (118)

1. Agarwal S.K., Guru S.C., Heppner C., Erdos M.R., Collins R.M., Park S.Y., Saggar S., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., Burns A.L. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96:143-152.
2. Arbour N.C., Ross T.K., Zierold C., Prahl J.M., DeLuca H.F. A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D. Anal. Biochem. 1998, 255:148-154.
3. Arcidiacono M.V., Cozzolino M., Spiegel N., Tokumoto M., Yang J., Lu Y., Sato T., Lomonte C., Basile C., Slatopolsky E., Dusso A.S. Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J. Am. Soc. Nephrol. 2008, 19:1919-1928.
4. Assemat E., Chatelet F., Chandellier J., Commo F., Cases O., Verroust P., Kozyraki R. Overlapping expression patterns of the multiligand endocytic receptors cubilin and megalin in the CNS, sensory organs and developing epithelia of the rodent embryo. Gene Expr. Patterns 2005, 6:69-78.
5. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10:482-496.
6. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
7. Bouillon R., Van Assche F.A., Van Baelen H., Heyns W., De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J. Clin. Invest. 1981, 67:589-596.
8. Brenza H.L., Kimmel-Jehan C., Jehan F., Shinki T., Wakino S., Anazawa H., Suda T., DeLuca H.F. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc. Natl. Acad. Sci. USA 1998, 95:1387-1391.
9. Brown A.J., Zhong M., Ritter C., Brown E.M., Slatopolsky E. Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem. Biophys. Res. Commun. 1995, 212:861-867.
10. Brown A.J., Zhong M., Finch J., Ritter C., McCracken R., Morrissey J., Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am. J. Physiol. 1996, 270:F454-F460.
11. Brumbaugh P.F., Haussler M.R. 1Alpha, 25-dihydroxyvitamin D3 receptor: competitive binding of vitamin D analogs. Life Sci. 1973, 13:1737-1746.
12. Canadillas S., Canalejo R., Rodriguez-Ortiz M.E., Martinez-Moreno J.M., Estepa J.C., Zafra R., Perez J., Munoz-Castaneda J.R., Canalejo A., Rodriguez M., Almaden Y. The up-regulation of the parathyroid VDR expression by extracellular calcium is mediated by the ERK1/2-MAPK signaling pathway. Am. J. Physiol. Renal Physiol. 2010, 298:1197-1204.
13. Canaff L., Hendy G.N. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem. 2002, 277:30337-30350.
14. Canalejo R., Canalejo A., Martinez-Moreno J.M., Rodriguez-Ortiz M.E., Estepa J.C., Mendoza F.J., Munoz-Castaneda J.R., Shalhoub V., Almaden Y., Rodriguez M. FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 2010, 21:1125-1135.
15. Carling T., Rastad J., Szabo E., Westin G., Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2000, 85:2000-2003.
16. Chen T.C. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anticancer Res. 2008, 28:2015-2017.
17. Chen R.A., Goodman W.G. Role of the calcium-sensing receptor in parathyroid gland physiology. Am. J. Physiol. Renal Physiol. 2004, 286:F1005-F1011.
18. Christensen M.H., Lien E.A., Hustad S., Almas B. Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scand. J. Clin. Lab. Invest. 2010, 70:281-286.
19. Cordero J.B., Cozzolino M., Lu Y., Vidal M., Slatopolsky E., Stahl P.D., Barbieri M.A., Dusso A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem. 2002, 277:38965-38971.
20. Correa P., Segersten U., Hellman P., Akerstrom G., Westin G. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors - new prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 2002, 87:5826-5829.
21. Cozzolino M., Lu Y., Finch J., Slatopolsky E., Dusso A.S. P21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001, 60:2109-2117.
22. Cozzolino M., Lu Y., Sato T., Yang J., Suarez I.G., Brancaccio D., Slatopolsky E., Dusso A.S. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am. J. Physiol. Renal Physiol. 2005, 289:F1096-F1102.
23. Cross H.S. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances. Nutr. Rev. 2007, 65:S108-S112.
24. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E., Josse R.G., Lips P., Morales-Torres J., Yoshimura N. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010, 21:1151-1154.
25. Deluca H.F., Prahl J.M., Plum L.A. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch. Biochem. Biophys. 2011, 505:226-230.
26. Demay M.B., Kiernan M.S., DeLuca H.F., Kronenberg H.M. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1992, 89:8097-8101.
27. Dhawan P., Peng X., Sutton A.L., MacDonald P.N., Croniger C.M., Trautwein C., Centrella M., McCarthy T.L., Christakos S. Functional cooperation between CCAAT/enhancer-binding proteins and the vitamin D receptor in regulation of 25-hydroxyvitamin D3 24-hydroxylase. Mol. Cell. Biol. 2005, 25:472-487.
28. Dreijerink K.M., Varier R.A., van Nuland R., Broekhuizen R., Valk G.D., van der Wal J.E., Lips C.J., Kummer J.A., Timmers H.T. Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol. Cell. Endocrinol. 2009, 313:1-8.
29. Dreijerink K.M., Lips C.J., Timmers H.T. Multiple endocrine neoplasia type 1: a chromatin writer's block. J. Intern. Med. 2009, 266:53-59.
30. Dusso A., Cozzolino M., Lu Y., Sato T., Slatopolsky E. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J. Steroid Biochem. Mol. Biol. 2004, 89-90:507-511.
31. Eisman J.A., DeLuca H.F. Intestinal 1,25-dihydroxyvitamin D3 binding protein: specificity of binding. Steroids 1977, 30:245-257.
32. Farnebo, F., Hoog, A., Sandelin, K., Larsson, C., Farnebo, L.O., 1998. Decreased expression of calcium-sensing receptor messenger ribonucleic acids in parathyroid adenomas. Surgery 124, 1094-1098 (discussion 1098-1099).
33. Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. 1993, 92:1436-1443.
34. Galitzer H., Ben-Dov I.Z., Silver J., Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010, 77:211-218.
35. Gobl A.E., Berg M., Lopez-Egido J.R., Oberg K., Skogseid B., Westin G. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim. Biophys. Acta 1999, 1447:51-56.
36. Gogusev J., Duchambon P., Stoermann-Chopard C., Giovannini M., Sarfati E., Drueke T.B. De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol. Dial. Transplant. 1996, 11:2155-2162.
37. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 2005, 90:2122-2126.
38. Guillemant J., Cabrol S., Allemandou A., Peres G., Guillemant S. Vitamin D-dependent seasonal variation of PTH in growing male adolescents. Bone 1995, 17:513-516.
39. Hagstrom E., Hellman P., Larsson T.E., Ingelsson E., Berglund L., Sundstrom J., Melhus H., Held C., Lind L., Michaelsson K., Arnlov J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119:2765-2771.
40. Henry H.L., Bouillon R., Norman A.W., Gallagher J.C., Lips P., Heaney R.P., Vieth R., Pettifor J.M., Dawson-Hughes B., Lamberg-Allardt C.J., Ebeling P.R. 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. J. Steroid Biochem. Mol. Biol. 2010, 121:4-6.
41. Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., Burns A.L. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
42. Ho C., Conner D.A., Pollak M.R., Ladd D.J., Kifor O., Warren H.B., Brown E.M., Seidman J.G., Seidman C.E. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 1995, 11:389-394.
43. Hofman-Bang J., Martuseviciene G., Santini M.A., Olgaard K., Lewin E. Increased parathyroid expression of Klotho in uremic rats. Kidney Int. 2010, 78:1119-11127.
44. Imanishi Y., Hosokawa Y., Yoshimoto K., Schipani E., Mallya S., Papanikolaou A., Kifor O., Tokura T., Sablosky M., Ledgard F., Gronowicz G., Wang T.C., Schmidt E.V., Hall C., Brown E.M., Bronson R., Arnold A. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J. Clin. Invest. 2001, 107:1093-1102.
45. Imura A., Tsuji Y., Murata M., Maeda R., Kubota K., Iwano A., Obuse C., Togashi K., Tominaga M., Kita N., Tomiyama K., Iijima J., Nabeshima Y., Fujioka M., Asato R., Tanaka S., Kojima K., Ito J., Nozaki K., Hashimoto N., Ito T., Nishio T., Uchiyama T., Fujimori T., Nabeshima Y. Alpha-Klotho as a regulator of calcium homeostasis. Science 2007, 316:1615-1618.
46. Inoue Y., Segawa H., Kaneko I., Yamanaka S., Kusano K., Kawakami E., Furutani J., Ito M., Kuwahata M., Saito H., Fukushima N., Kato S., Kanayama H.O., Miyamoto K. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 2005, 390:325-331.
47. Inouye K., Sakaki T. Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol. Annu. Rev. 2001, 7:179-194.
48. Jaaskelainen T., Ryhanen S., Mahonen A., DeLuca H.F., Maenpaa P.H. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J. Cell. Biochem. 2000, 76:548-558.
49. Jean G., Souberbielle J.C., Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol. Dial. Transplant. 2009, 24:3799-3805.
50. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003, 284:31-53.
51. Kallay E., Bises G., Bajna E., Bieglmayer C., Gerdenitsch W., Steffan I., Kato S., Armbrecht H.J., Cross H.S. Colon-specific regulation of vitamin D hydroxylases - a possible approach for tumor prevention. Carcinogenesis 2005, 26:1581-1589.
52. Kandula P., Dobre M., Schold J.D., Schreiber M.J., Mehrotra R., Navaneethan S.D. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 2011, 6:50-62.
53. Kawahara M., Iwasaki Y., Sakaguchi K., Taguchi T., Nishiyama M., Nigawara T., Tsugita M., Kambayashi M., Suda T., Hashimoto K. Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 2008, 82:677-683.
54. Kim M.S., Fujiki R., Murayama A., Kitagawa H., Yamaoka K., Yamamoto Y., Mihara M., Takeyama K., Kato S. 1Alpha, 25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol. Endocrinol. 2007, 21:334-342.
55. Kim M.S., Kondo T., Takada I., Youn M.Y., Yamamoto Y., Takahashi S., Matsumoto T., Fujiyama S., Shirode Y., Yamaoka I., Kitagawa H., Takeyama K., Shibuya H., Ohtake F., Kato S. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
56. Komaba H., Goto S., Fujii H., Hamada Y., Kobayashi A., Shibuya K., Tominaga Y., Otsuki N., Nibu K., Nakagawa K., Tsugawa N., Okano T., Kitazawa R., Fukagawa M., Kita T. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010, 77:232-238.
57. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., Westin G., Larsson T.E. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
58. Krajisnik T., Olauson H., Mirza M.A., Hellman P., Akerstrom G., Westin G., Larsson T.E., Bjorklund P. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 2010, 78:1024-1032.
59. Kumata C., Mizobuchi M., Ogata H., Koiwa F., Nakazawa A., Kondo F., Kadokura Y., Kinugasa E., Akizawa T. Involvement of alpha-Klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am. J. Nephrol. 2010, 31:230-238.
60. Lauter K., Arnold A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J. Bone Miner. Res. 2009, 24:102-104.
61. Leheste J.R., Melsen F., Wellner M., Jansen P., Schlichting U., Renner-Muller I., Andreassen T.T., Wolf E., Bachmann S., Nykjaer A., Willnow T.E. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 2003, 17:247-249.
62. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10:142-153.
63. Liu W., Ridefelt P., Akerstrom G., Hellman P. Differentiation of human parathyroid cells in culture. J. Endocrinol. 2001, 168:417-425.
64. Lopes N., Sousa B., Martins D., Gomes M., Vieira D., Veronese L.A., Milanezi F., Paredes J., Costa J.L., Schmitt F. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions vitamin D pathways unbalanced in breast lesions. BMC Cancer 2010, 10:483.
65. Lundgren S., Carling T., Hjalm G., Juhlin C., Rastad J., Pihlgren U., Rask L., Akerstrom G., Hellman P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J. Histochem. Cytochem. 1997, 45:383-392.
66. Mackey S.L., Heymont J.L., Kronenberg H.M., Demay M.B. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol. Endocrinol. 1996, 10:298-305.
67. Martuseviciene G., Hofman-Bang J., Clausen T., Olgaard K., Lewin E. The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int. 2011, 79:742-748.
68. Matias P.J., Jorge C., Ferreira C., Borges M., Aires I., Amaral T., Gil C., Cortez J., Ferreira A. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 2010, 5:905-911.
69. Meir T., Levi R., Lieben L., Libutti S., Carmeliet G., Bouillon R., Silver J., Naveh-Many T. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am. J. Physiol. Renal Physiol. 2009, 297:F1192-F1198.
70. Mellon W.S., DeLuca H.F. An equilibrium and kinetic study of 1,25-dihydroxyvitamin D3 binding to chicken intestinal cytosol employing high specific activity 1,25-dehydroxy [3H-26,27] vitamin D3. Arch. Biochem. Biophys. 1979, 197:90-95.
71. Michaud J., Naud J., Ouimet D., Demers C., Petit J.L., Leblond F.A., Bonnardeaux A., Gascon-Barre M., Pichette V. Reduced hepatic synthesis of calcidiol in uremia. J. Am. Soc. Nephrol. 2010, 21:1488-1497.
72. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Hosoya T., Kato S. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha, 25(OH)2D3. Biochem. Biophys. Res. Commun. 1998, 249:11-16.
73. Murayama A., Kim M.S., Yanagisawa J., Takeyama K., Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J. 2004, 23:1598-1608.
74. Naveh-Many T., Marx R., Keshet E., Pike J.W., Silver J. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J. Clin. Invest. 1990, 86:1968-1975.
75. Nygren P., Larsson R., Johansson H., Ljunghall S., Rastad J., Akerstrom G. 1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif. Tissue Int. 1988, 43:213-218.
76. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., Melsen F., Christensen E.I., Willnow T.E. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
77. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., Goltzman D. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 2004, 279:16754-16766.
78. Pascussi J.M., Robert A., Nguyen M., Walrant-Debray O., Garabedian M., Martin P., Pineau T., Saric J., Navarro F., Maurel P., Vilarem M.J. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 2005, 115:177-186.
79. Pearce S.H., Williamson C., Kifor O., Bai M., Coulthard M.G., Davies M., Lewis-Barned N., McCredie D., Powell H., Kendall-Taylor P., Brown E.M., Thakker R.V. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 1996, 335:1115-1122.
80. Potts J.T., Gardella T.J. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann. N.Y. Acad. Sci. 2007, 1117:196-208.
81. Prie D., Urena Torres P., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009, 75:882-889.
82. Ritter C.S., Brown A.J. Direct suppression of PTH gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J. Mol. Endocrinol. 2011, 46:63-66.
83. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006, 70:654-659.
84. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., Durazo-Arvizu R.A., Gallagher J.C., Gallo R.L., Jones G., Kovacs C.S., Mayne S.T., Rosen C.J., Shapses S.A. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96:53-58.
85. Rowling M.J., Gliniak C., Welsh J., Fleet J.C. High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. J. Nutr. 2007, 137:2608-2615.
86. Safadi F.F., Thornton P., Magiera H., Hollis B.W., Gentile M., Haddad J.G., Liebhaber S.A., Cooke N.E. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J. Clin. Invest. 1999, 103:239-251.
87. Sai A.J., Walters R.W., Fang X., Gallagher J.C. Relationship between vitamin D, parathyroid hormone, and bone health. J. Clin. Endocrinol. Metab. 2011, 96:E436-E446.
88. Sakaguchi K., Santora A., Zimering M., Curcio F., Aurbach G.D., Brandi M.L. Functional epithelial cell line cloned from rat parathyroid glands. Proc. Natl. Acad. Sci. USA 1987, 84:3269-3273.
89. Sakaguchi K., Ikeda K., Curcio F., Aurbach G.D., Brandi M.L. Subclones of a rat parathyroid cell line (PT-r): regulation of growth and production of parathyroid hormone-related peptide (PTHRP). J. Bone Miner. Res. 1990, 5:863-869.
90. Sambrook P.N., Chen J.S., March L.M., Cameron I.D., Cumming R.G., Lord S.R., Schwarz J., Seibel M.J. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J. Clin. Endocrinol. Metab. 2004, 89:5477-5481.
91. Schwartz M.M., Bidani A.K. Comparison of glomerular injury in juvenile versus mature rats in a remnant kidney model. J. Lab. Clin. Med. 1993, 121:348-355.
92. Schwartz G.G., Eads D., Rao A., Cramer S.D., Willingham M.C., Chen T.C., Jamieson D.P., Wang L., Burnstein K.L., Holick M.F., Koumenis C. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 2004, 25:1015-1026.
93. Segersten U., Correa P., Hewison M., Hellman P., Dralle H., Carling T., Akerstrom G., Westin G. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 2002, 87:2967-2972.
94. Segersten U., Bjorklund P., Hellman P., Akerstrom G., Westin G. Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells. Clin. Endocrinol. (Oxf.) 2007, 66:399-404.
95. Shinki T., Jin C.H., Nishimura A., Nagai Y., Ohyama Y., Noshiro M., Okuda K., Suda T. Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1 alpha, 25-dihydroxyvitamin D3 in rat kidney but not in intestine. J. Biol. Chem. 1992, 267:13757-13762.
96. Silver J., Russell J., Sherwood L.M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 1985, 82:4270-4273.
97. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 1986, 78:1296-1301.
98. Souberbielle J.C., Maury E., Friedlander G., Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J. Steroid Biochem. Mol. Biol. 2010, 121:199-203.
99. St-Arnaud R., Arabian A., Travers R., Barletta F., Raval-Pandya M., Chapin K., Depovere J., Mathieu C., Christakos S., Demay M.B., Glorieux F.H. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
100. St-Arnaud R. CYP24A1-deficient mice as a tool to uncover a biological activity for vitamin D metabolites hydroxylated at position 24. J. Steroid Biochem. Mol. Biol. 2010, 121:254-256.
101. Szabo A., Merke J., Beier E., Mall G., Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989, 35:1049-1056.
102. Takeyama K., Kitanaka S., Sato T., Kobori M., Yanagisawa J., Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
103. Taniguchi M., Tokumoto M., Matsuo D., Tsuruya K., Hirakata H., Iida M. Parathyroid growth and regression in experimental uremia. Kidney Int. 2006, 69:464-470.
104. Tokumoto M., Tsuruya K., Fukuda K., Kanai H., Kuroki S., Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002, 62:1196-1207.
105. Tokumoto M., Taniguchi M., Matsuo D., Tsuruya K., Hirakata H., Iida M. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther. Apher. Dial. 2005, 9(Suppl. 1):S27-S34.
106. Tomida K., Hamano T., Mikami S., Fujii N., Okada N., Matsui I., Nagasawa Y., Moriyama T., Ito T., Imai E., Isaka Y., Rakugi H. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 2009, 44:678-683.
107. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
108. Vieth R., Ladak Y., Walfish P.G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 2003, 88:185-191.
109. Vieth R. Vitamin D nutrient to treat TB begs the prevention question. Lancet 2011, 377:189-190.
110. Wang X., Sun B., Zhou F., Hu J., Yu X., Peng T. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin. Med. J. (Engl.) 2001, 114:410-414.
111. Wei S., Tanaka H., Seino Y. Local action of exogenous growth hormone and insulin-like growth factor-I on dihydroxy vitamin D production in LLC-PK1 cells. Eur. J. Endocrinol. 1998, 139:454-460.
112. Wiese R.J., Uhland-Smith A., Ross T.K., Prahl J.M., DeLuca H.F. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J. Biol. Chem. 1992, 267:20082-20086.
113. Wu S., Finch J., Zhong M., Slatopolsky E., Grieff M., Brown A.J. Expression of the renal 25-hydroxyvitamin D-24-hydroxylase gene: regulation by dietary phosphate. Am. J. Physiol. 1996, 271:F203-F218.
114. Yendt E.R., Kovacs K.A., Jones G. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction. Clin. Endocrinol. (Oxf.) 2008, 69:855-863.
115. Young M.V., Schwartz G.G., Wang L., Jamieson D.P., Whitlatch L.W., Flanagan J.N., Lokeshwar B.L., Holick M.F., Chen T.C. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25:967-971.
116. Zhong Y., Armbrecht H.J., Christakos S. Calcitonin, a regulator of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene. J. Biol. Chem. 2009, 284:11059-11069.
117. Zhou C., Assem M., Tay J.C., Watkins P.B., Blumberg B., Schuetz E.G., Thummel K.E. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J. Clin. Invest. 2006, 116:1703-1712.
118. Zierold C., Mings J.A., DeLuca H.F. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J. Cell. Biochem. 2003, 88:234-237.